$99.30
+8.28 (+9.10%)
Open$92.83
Previous Close$91.02
Day High$100.17
Day Low$91.00
52W High$104.00
52W Low$15.83
Volume—
Avg Volume868.7K
Market Cap6.17B
P/E Ratio—
EPS$-4.19
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
-87.1% upside
Current
$99.30
$99.30
Target
$12.80
$12.80
$8.80
$12.80 avg
$18.52
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 639.02M | 671.15M | 526.83M |
| Net Income | 3.07M | 3.06M | 2.31M |
| Profit Margin | 0.5% | 0.5% | 0.4% |
| EBITDA | 3.98M | 4.67M | 3.27M |
| Free Cash Flow | 2.86M | 3.84M | 2.49M |
| Rev Growth | +2.1% | +18.5% | -6.0% |
| Debt/Equity | 0.55 | 0.45 | 0.49 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |